Stockscreener 앱 받기
6.91
5.73%
-0.42
Envveno Medical Corp 주식(NVNO)의 최신 뉴스
A severe vein condition has few effective treatments. A new video explores how many people have it. - Stock Titan
enVVeno Medical Corp (NASDAQ: NVNO) Activist Ownership Drops to Zero Following Complete Stake Sale - kalkinemedia.com
Two major holders fully exit enVVeno Medical Corp (NVNO) - Stock Titan
Braeden Lichti Files Exit Filing at enVVeno - marketscreener.com
Director Francis Duhay Sells 11 Shares of enVVeno Medical Corp (NVNO) - GuruFocus
enVVeno Medical (NVNO) director logs small preset stock sale - Stock Titan
Enveno medical director Francis Duhay sells $123 in shares - Investing.com
Director at enVVeno (NASDAQ: NVNO) plans sale of 11 shares - Stock Titan
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - ACCESS Newswire
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - The Joplin Globe
A medical-device CEO's presentation is now online ahead of New York meetings - Stock Titan
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - ACCESS Newswire
EnVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - marketscreener.com
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - Barchart.com
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - The Joplin Globe
enVVeno Medical files prospectus to offer securities for up to $100 million - scanx.trade
enVVeno Medical (NASDAQ: NVNO) readies $100M in potential securities sales - Stock Titan
Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants - Stock Titan
NVNO Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 8.54%Estimate Uncertainty - Vinanet
NVNO Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development CostsEPS Consistency Score - vinanet.vn
enVVeno study shows $32,000 savings per patient for venous valve therapy - scanx.trade
enVVeno Medical (NVNO) Highlights Cost-Effectiveness of VenoValve Amid Challenging Valuation Metrics - GuruFocus
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - ACCESS Newswire
enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient - Stock Titan
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - Yahoo Finance
enVVeno cites Journal of Vascular Surgery study showing venous valve therapy saves more than $32,000 per patient over five years - Bitget
EnVVeno Moves Toward U.S. Pivotal Trial - Orange County Business Journal
enVVeno Medical receives FDA approval for pivotal trial By Investing.com - Investing.com Nigeria
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve - Weatherford Democrat
FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO) - Stock Titan
NVNO Q2'26 Earnings: EPS estimate is (4.69) USD - TradingView
enVVeno Medical Corp (NVNO) Cash Flow - TradingKey
enVVeno Medical Corp expected to post a loss of $4.69 a shareEarnings Preview - TradingView
enVVeno Medical Corporation Revenue Breakdown – LS:A42085 - TradingView
enVVeno Medical Corp (NVNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
enVVeno Medical Corp (NVNO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
enVVeno Medical Corp (NVNO) Income Statement - TradingKey
NVNO|enVVeno Medical Corp|Price:10.390|Chg%:+0.160 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineEarnings Expansion Phase - dars.gov.et
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineSaaS Earnings Trends - Vinanet
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchZigzag Correction - dars.gov.et
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchRSI Overbought Alerts - dars.gov.et
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchOpening Range Breakout - Vinanet
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineBanking Earnings Report - po-news-eg.net
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineProfit Guidance Range - dars.gov.et
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineEarnings Weakness Phase - vinanet.vn
NVNO Q3 2025 Earnings: Narrower Loss Than Expected as enVVeno Controls CostsDividend Cut Risk - vinanet.vn
2.72%
1.62%
자본화:
|
볼륨(24시간):